5jm5
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Crystal structure of AKR1C3 complexed with a pro-drug== | |
| - | + | <StructureSection load='5jm5' size='340' side='right' caption='[[5jm5]], [[Resolution|resolution]] 1.99Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[5jm5]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5JM5 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5JM5 FirstGlance]. <br> | |
| - | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=6LG:(1R)-1-{3-[3-(DIMETHYLCARBAMOYL)PHENOXY]-4-NITROPHENYL}ETHYL+BIS[(AZIRIDIN-1-YL)]PHOSPHINATE'>6LG</scene>, <scene name='pdbligand=6NY:3-{2-(HYDROXYAMINO)-5-[(1S)-1-HYDROXYETHYL]PHENOXY}-N,N-DIMETHYLBENZAMIDE'>6NY</scene>, <scene name='pdbligand=NAP:NADP+NICOTINAMIDE-ADENINE-DINUCLEOTIDE+PHOSPHATE'>NAP</scene></td></tr> | |
| - | [[ | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5jm5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5jm5 OCA], [http://pdbe.org/5jm5 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5jm5 RCSB], [http://www.ebi.ac.uk/pdbsum/5jm5 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5jm5 ProSAT]</span></td></tr> |
| - | [[Category: | + | </table> |
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/AK1C3_HUMAN AK1C3_HUMAN]] Catalyzes the conversion of aldehydes and ketones to alcohols. Catalyzes the reduction of prostaglandin (PG) D2, PGH2 and phenanthrenequinone (PQ) and the oxidation of 9-alpha,11-beta-PGF2 to PGD2. Functions as a bi-directional 3-alpha-, 17-beta- and 20-alpha HSD. Can interconvert active androgens, estrogens and progestins with their cognate inactive metabolites. Preferentially transforms androstenedione (4-dione) to testosterone. | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Li, Q]] | ||
[[Category: Wang, C]] | [[Category: Wang, C]] | ||
| - | [[Category: Li, Q]] | ||
[[Category: Wang, Z]] | [[Category: Wang, Z]] | ||
| + | [[Category: Xie, W]] | ||
| + | [[Category: Akr1c3]] | ||
| + | [[Category: Inhibitor]] | ||
| + | [[Category: Liver cancer]] | ||
| + | [[Category: Oxidoreductase-oxidoreductase inhibitor complex]] | ||
| + | [[Category: Pro-drug]] | ||
Revision as of 13:08, 4 May 2017
Crystal structure of AKR1C3 complexed with a pro-drug
| |||||||||||
